Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis

Abstract EN

Background.

Treatment of schizophrenia with first- and second-generation antipsychotics has been associated with elevated prolactin levels, which may increase the risk for prolactin-related adverse events.

Methods.

Randomized controlled trials (RCTs) included in a recent systematic review were considered for this analysis.

A Bayesian network meta-analysis was used to compare changes in prolactin levels in pediatric patients diagnosed with schizophrenia or schizophrenia spectrum disorders treated with second-generation antipsychotics (SGAs).

Results.

Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone.

In the overall study population, treatment with risperidone was associated with the highest increase in mean prolactin levels compared to other SGAs.

Patients treated with risperidone 4–6 mg/day were found to experience the greatest increases (55.06 ng/ml [95% CrI: 40.53–69.58]) in prolactin levels, followed by risperidone 1–3 mg/day, paliperidone 3–6 mg/day, and paliperidone 6–12 mg/day.

Conclusions.

This study shows that there are differences in SGAs ability to cause hyperprolactinemia.

Further, there is clear evidence of safety concerns with risperidone and paliperidone treatment in adolescent schizophrenia patients.

Registration.

PROSPERO CRD42014009506.